Renhe Pharmaceutical announced that as of August 5, 2026, the company has completed share repurchases. This time, a total of 17.705 million shares were repurchased through centralized bidding transactions, accounting for 1.2643% of the company's total share capital. The total transaction amount was 99.996 million yuan, and the repurchase price was 4.86 yuan/share - 5.73 yuan/share. This repurchase complies with relevant regulations and will not have a significant impact on the company's operations, profitability, etc. The repurchase of shares is intended to be used in employee shareholding or equity incentive plans, and will be cancelled if not approved or granted.

Renhe Pharmaceutical announced that as of August 5, 2026, the company has completed share repurchases. This time, a total of 17.705 million shares were repurchased through centralized bidding transactions, accounting for 1.2643% of the company's total share capital. The total transaction amount was 99.996 million yuan, and the repurchase price was 4.86 yuan/share - 5.73 yuan/share. This repurchase complies with relevant regulations and will not have a significant impact on the company's operations, profitability, etc. Shares are to be repurchased for employee shareholding or equity incentive plans, and will be cancelled if not approved or granted.